Fresenius Medical Care (NYSE:FMS) Upgraded at Bank of America

Fresenius Medical Care (NYSE:FMS) was upgraded by equities researchers at Bank of America from an “underperform” rating to a “neutral” rating in a report released on Monday,Finviz reports.

Several other research analysts have also weighed in on the stock. Truist Financial increased their price objective on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the stock a “hold” rating in a report on Monday, October 7th. StockNews.com started coverage on shares of Fresenius Medical Care in a research note on Thursday. They issued a “strong-buy” rating on the stock. Finally, Berenberg Bank initiated coverage on shares of Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price objective for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $24.30.

Fresenius Medical Care Stock Performance

NYSE:FMS opened at $22.52 on Monday. Fresenius Medical Care has a fifty-two week low of $17.93 and a fifty-two week high of $22.76. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. The stock has a market cap of $13.22 billion, a PE ratio of 18.61, a price-to-earnings-growth ratio of 1.01 and a beta of 0.91. The firm’s fifty day simple moving average is $20.97 and its 200-day simple moving average is $20.30.

Institutional Trading of Fresenius Medical Care

Several hedge funds have recently added to or reduced their stakes in the business. Wulff Hansen & CO. raised its holdings in Fresenius Medical Care by 1,809.0% in the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after acquiring an additional 325,439 shares in the last quarter. Moran Wealth Management LLC raised its stake in Fresenius Medical Care by 47.0% during the third quarter. Moran Wealth Management LLC now owns 233,376 shares of the company’s stock worth $4,971,000 after acquiring an additional 74,621 shares in the last quarter. Quantinno Capital Management LP lifted its holdings in Fresenius Medical Care by 78.9% during the 3rd quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock valued at $2,345,000 after purchasing an additional 48,554 shares during the last quarter. Crossmark Global Holdings Inc. raised its position in Fresenius Medical Care by 60.4% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 62,889 shares of the company’s stock valued at $1,340,000 after purchasing an additional 23,692 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Fresenius Medical Care in the third quarter valued at about $420,000. Institutional investors own 8.25% of the company’s stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.